Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Medicare Formulary Standards Will Have More “Granularity” Than USP

This article was originally published in The Pink Sheet Daily

Executive Summary

The Centers for Medicare & Medicaid Services expects its reviews of Medicare Rx drug plan formularies to include evaluation of drug choices at the “sub-class” level. The standards will also aim to encourage plans to provide more than the minimum two drugs per formulary class.
Advertisement

Related Content

CMS Finalizing Plans For Medicare Rx Regions, Formulary Standards
CMS Finalizing Plans For Medicare Rx Regions, Formulary Standards
Medicare Rx “Dual Eligibles” Will Influence Formulary Design, Insurer Says
Medicare Rx “Dual Eligibles” Will Influence Formulary Design, Insurer Says
Lawmakers Begin Lobbying CMS Over Medicare Drug Formularies
Lawmakers Begin Lobbying CMS Over Medicare Drug Formularies
Medicare Rx Formularies Need Independent "Watchdog," Consumers Union Says
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
COX-2s Left Out Of Drug Classes, Will Go Up Against Other NSAIDs

Topics

Advertisement
UsernamePublicRestriction

Register

PS060353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel